Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Fosun
Fosun
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Fosun Pharma invests $50m in BioNTech for its COVID-19 vaccine
The two companies have agreed to develop BNT162 in China leveraging Fosun’s capabilities in the country
Finance
Chinese facility changes hands from GSK to Fosun Pharmaceutical
The deal has been reported to be worth US$36 million
Finance
ReNeuron and Fosun Pharma join forces in China
For exclusive rights to its CTX and hRPC cell therapy programmes, ReNeuron will receive £6 million upfront, and approximately £80 million in milestone payments
Regulatory
Sirona Biochem announces SGLT2 IND submission
Sirona Biochem announced its partner Wanbang Biopharmaceuticals has confirmed an investigational new drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor
Subscribe now